Viatris, Inc. (VTRS)

Viatris's stock price has experienced a significant decline in the past six months. Key events impacting the stock include disappointing Q4 2024 results, regulatory challenges at the Indore facility, lowered 2025 guidance, and a goodwill impairment charge.

Viatris expects its total revenues to be higher in the second half of the year due to the launch of new products and normal product seasonality.

Viatris Inc. is a global healthcare company formed in November 2020 through the merger of Mylan N.V. and Upjohn, a division of Pfizer, focusing on drug manufacturing. It provides a broad range of medicines, including generics, branded medications, biosimilars, and over-the-counter products, across various key therapeutic areas. Its portfolio includes globally recognized brands and generics, as well as complex products, with notable products including Insulin Glargine, Fulphila, Generic EpiPen, Lipitor, Viagra, Breyna, Wixela, and Yupelri. The company also operates manufacturing sites worldwide that produce oral solid doses, injectables, and complex dosage forms.

Viatris has an extensive global presence, operating in over 165 countries and territories. Its operations are segmented into Developed Markets, Greater China, JANZ, and Emerging Markets. Viatris also maintains 37 manufacturing sites globally across six continents.

Viatris has received several accolades in previous years, indicating a positive brand reputation, including listings on Forbes' World's Best Employers and USA Today's America's Climate Leaders. The company has also received Great Place to Work® and Top Employers certifications in multiple countries. However, regulatory challenges at its Indore facility and the subsequent financial impact could indirectly affect stakeholder perception and reputation.

Viatris Inc. has a mixed ownership structure, with a significant portion held by institutional investors, approximately 73.90% to 81.63%. Insiders own around 0.24% to 18.14%, and public companies and individual investors hold the remaining shares. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., Price T Rowe Associates Inc /md/, Davis Selected Advisers, State Street Corp, Geode Capital Management, Llc, and Invesco Ltd. Laboratories Abbott is a large individual shareholder.